{
    "nctId": "NCT00999557",
    "briefTitle": "Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants",
    "officialTitle": "Efficacy of Topical Bimatoprost in Promoting Hair Growth in the Region of the Eyebrow and Eyelashes for Post-chemotherapy Patients Versus Normal Patients",
    "overallStatus": "WITHDRAWN",
    "conditions": "Alopecia, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Measuring regrowth of eyebrows and eyelashes by Bimatoprost Opthalmic solution",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Meets 1 of the following criteria:\n* Diagnosis of breast cancer (group 1)\n* Completed chemotherapy within the past month that has resulted in eyebrow alopecia or eyelash hypotrichosis\n* Eyebrow score of 0-2 or eyelash score of 0-2 on the study's qualitative eyebrow or eyelash growth chart\n* Has no known underlying disease (group 2)\n* Desires thicker, fuller, or more numerous eyebrows\n\nExclusion criteria\n\n* pregnant\n* does not Speak a language adequately covered by study translator services\n* cognitive impairment\n* history of trauma or burn to the eyebrow region, alopecia areata, or trichotillomania\n* known diagnoses possibly underlying or contributing to the state of the eyebrows including, but not limited to, telogen effluvium or anagen effluvium (group 2)\n* active ocular disease (group 1)\n* thyroid hormone level abnormalities (group 2)\n* More than 2 years since prior ocular surgery (group 1)\n* prior topical medication for increasing eyebrow growth within 30 days od starting study treatment\n* concomitant chemotherapy for the treatment of cancer (group 1)\n* concomitant therapy for eyelash or eyebrow growth",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}